These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 6897834)

  • 21. The effects of triglyceride absorption upon glucagon, insulin, and gut glucagon-like immunoreactivity.
    Böttger I; Dobbs R; Faloona GR; Unger RH
    J Clin Invest; 1973 Oct; 52(10):2532-41. PubMed ID: 4738064
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The normal range of the plasma immunoreactive glucagon level during a 75 g oral glucose tolerance test.
    Shima K; Hirota M; Nakamura K; Kodaira T
    Diabetes Res Clin Pract; 1985-1986 Feb; 1(5):265-71. PubMed ID: 3841774
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasma glucagon-like immunoreactivity (GLI) in dogs.
    Oneda A; Horigome K; Yanbe A; Ishii S; Itabashi H
    Tohoku J Exp Med; 1975 Apr; 115(4):337-43. PubMed ID: 1145615
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of hypophysectomy and hypophysis-transplantation on the secretion of gut glucagon immunoreactivity and gut glucagon-like immunoreactivity in depancreatized dogs.
    Yoshida T; Kondo M
    Endocrinol Jpn; 1980 Feb; 27(1):77-81. PubMed ID: 6248336
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma glucagon and glucagon-like immunoreactive components in Type 1 (insulin-dependent) diabetic patients and normal subjects before and after an oral glucose load.
    Rovira A; Garrote FJ; Pascual JM; Salvador MG; Herrera Pombo JL; Valverde I
    Diabetologia; 1985 Feb; 28(2):80-6. PubMed ID: 3838521
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evidence for the presence of glucagon-like immunoreactivity (GLI) in the pancreas.
    Srikant CB; Unger RH
    Endocrinology; 1976 Dec; 99(6):1655-8. PubMed ID: 1001259
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship between insulin and gut glucagon-like immunoreactivity (GLI) secretion in normal and gastrectomized subjects.
    Marco J; Baroja IM; Diaz-Fierros M; Villanueva ML; Valverde I
    J Clin Endocrinol Metab; 1972 Jan; 34(1):188-91. PubMed ID: 5008225
    [No Abstract]   [Full Text] [Related]  

  • 28. Identification of glucagon in the gastrointestinal tract.
    Sasaki H; Rubalcava B; Baetens D; Blazquez E; Srikant CB; Orci L; Unger RH
    J Clin Invest; 1975 Jul; 56(1):135-45. PubMed ID: 237936
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Production and characterization of N-terminally and C-terminally directed monoclonal antibodies against pancreatic glucagon.
    Gregor M; Riecken EO
    Gastroenterology; 1985 Sep; 89(3):571-80. PubMed ID: 3839481
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of phenformin upon the plasma pancreatic and gut glucagon-like immunoreactivity in diabetics.
    Czyzyk A; Heding LG; Malczewski B; Miedzinska E
    Diabetologia; 1975 Apr; 11(2):129-33. PubMed ID: 168107
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of an oxyntomodulin/glicentin C-terminal radioimmunoassay using a "thiol-maleoyl" coupling method for preparing the immunogen.
    Blache P; Kervran A; Martinez J; Bataille D
    Anal Biochem; 1988 Aug; 173(1):151-9. PubMed ID: 3189794
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Radioimmunoassay of plasma pancreatic glucagon using a specific anti-glucagon sera (OAL-123) (author's transl)].
    Nishimura N; Chikamori K; Saito S
    Horumon To Rinsho; 1980 Sep; 28(9):1109-13. PubMed ID: 7460363
    [No Abstract]   [Full Text] [Related]  

  • 33. [Total GLI (glucagon-like immunoreactivity) radioimmunoassay kit--experimental study].
    Isoda Y; Tominaga M; Marubashi S; Kaneda H; Sasaki H
    Horumon To Rinsho; 1982 Dec; 30(12):1427-31. PubMed ID: 7160089
    [No Abstract]   [Full Text] [Related]  

  • 34. Effect of acetylcholine on the secretion of gut glucagon immunoreactivity and gut glucagon-like immunoreactivity in pancreatectomized dogs.
    Yoshida T; Kondo M
    Endocrinol Jpn; 1980 Feb; 27(1):33-8. PubMed ID: 6993193
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glucagon carboxyl-terminal derivatives: preparation, purification, and characterization.
    England RD; Jones BN; Flanders KC; Coolican SA; Rothgeb TM; Gurd RS
    Biochemistry; 1982 Mar; 21(5):940-50. PubMed ID: 7074063
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glucagon-related peptides in the rat hypothalamus.
    Inokuchi A; Tomida Y; Yanaihara C; Yui R; Oomura Y; Kimura H; Hase T; Matsumoto T; Yanaihara N
    Cell Tissue Res; 1986; 246(1):71-5. PubMed ID: 3779802
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gut glucagon, enteroglucagon, gut glucagonlike immunoreactivity, glicentin--current status.
    Holst JJ
    Gastroenterology; 1983 Jun; 84(6):1602-13. PubMed ID: 6188645
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Extrapancreatic glucagons.
    Holst JJ
    Digestion; 1978; 17(2):168-90. PubMed ID: 342323
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Decrease in blood glucose and release of gut glucagon-like immunoreactive materials by bombesin infusion in the dog.
    Matsuyama T; Namba M; Nonaka K; Tarui S; Tanaka R; Shima K
    Endocrinol Jpn; 1980 Dec; 27 Suppl 1():115-9. PubMed ID: 7014201
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of calcium and other salts upon the release of glucagon-like immunoreactivity from the gut.
    Böttger I; Faloona GR; Unger RH
    J Clin Invest; 1972 Apr; 51(4):831-6. PubMed ID: 5014613
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.